| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2190 |
| Trial ID | NCT04094311 |
| Disease | B-Cell Acute Lymphoblastic Leukemia | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | Study of Out of Specification for Tisagenlecleucel |
| Year | 2019 |
| Country | Canada|Japan |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019B2302 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||